Print

Novo Nordisk A/S (NVO): Previously Announced FDA Warning Letter Published  
2/5/2013 10:15:13 AM

BAGSVAERD, DENMARK--(Marketwire - February 05, 2013) -


Company announcement No 10 / 2013: http://hugin.info/2013/R/1675578/545854.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1675578]


Further information:
Media:
Mike Rulis
Tel: +45 3079 3573
Email Contact

Lori Moore
+1 609 919 7991
Email Contact

Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact


//-->